Eduardo Kanterewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eduardo Kanterewicz has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Emma Puigoriol-Juvanteny
Epidemiology Department, Hospital Universitari de Vic, 08500 Vic, Spain
8 shared publications P. Peris
Department of Rheumatology, Hospital Clínic i Provincial, Barcelona, Spain
4 shared publicationsPilar Peris
Hospital Clínic i Provincial, CIBERehd
3 shared publications- Aina Maria Yanez
Research Group on Global Health, University of Balearic Islands
2 shared publications - Alba Erra
Hospital Universitari de Bellvitge, Spain
2 shared publications - Ana Monegal
Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Spain
2 shared publications
Latest Publications
- Open Access
- 20 April 2021
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 36 (11) , 2275-2276
Grade 1 vertebral fractures, bone mineral density, and the risk of fractures
- 20 April 2021
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 36 (11) , 2275-2276
Open AccessGrade 1 vertebral fractures, bone mineral density, and the risk of fractures
- 17 July 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (9) , 1901-1902
Correction to: Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study
Figure 1 as published in the original version of this article was unfortunately incomplete.
- 17 July 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (9) , 1901-1902
Correction to: Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study
Figure 1 as published in the original version of this article was unfortunately incomplete.
- 23 May 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (10) , 2141-2149
Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study
The incidence of vertebral fractures (VF) by vertebral fracture assessment (VFA) was 6.6% in postmenopausal women (FRODOS cohort) after 4 years of follow-up, increasing with prevalent VF and minor vertebral deformities, age, lower bone mass, glucocorticoid use, and rheumatoid arthritis. This study supports the usefulness of VFA to identify VF.
- 23 May 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (10) , 2141-2149
Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study
The incidence of vertebral fractures (VF) by vertebral fracture assessment (VFA) was 6.6% in postmenopausal women (FRODOS cohort) after 4 years of follow-up, increasing with prevalent VF and minor vertebral deformities, age, lower bone mass, glucocorticoid use, and rheumatoid arthritis. This study supports the usefulness of VFA to identify VF.
- 1 April 2018
- Published by Elsevier in Revista Clínica Española
- Vol. 218 (3) , 121-127
Utilidad del Trabecular Bone Score en la valoración del riesgo de fractura osteoporótica
- 1 April 2018
- Published by Elsevier in Revista Clínica Española
- Vol. 218 (3) , 121-127
Utilidad del Trabecular Bone Score en la valoración del riesgo de fractura osteoporótica
- 1 December 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 475, 169-171
Concordance between direct and indirect measurements of free 25-OH vitamin D
- 1 December 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 475, 169-171
Concordance between direct and indirect measurements of free 25-OH vitamin D
- 2 May 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 28 (8) , 2457-2464
Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study
Summary Determination of different forms of 25-OHD (total, free and bioavailable) in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values T), DBP, albumin, PTH and bone formation (PINP,OC) and resorption (NTx,CTx) markers. Free(25-OHDF) and bioavailable (25-OHDB) serum 25-OHD levels were estimated by DBP and albumin determinations and also directly by ELISA (25-OHDF-2). We analysed threshold PTH values for the different forms of 25-OHD and the correlations and differences according to 25-OHDT levels T (15.4 ± 1.4 vs. 18.3 ± 2.7, p < 0.05) and 25OHDB values (1.7 ± 0.2 vs. 2.2 ± 0.09, p < 0.05). The different forms of 25OHD were significantly intercorrelated, with marginal correlations between PTH and 25-OHDT (r = −0.136, p = 0.082). Conclusions Determination of different forms of 25-OHD in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values <15 ng/ml would be more appropriate for defining this deficiency.
- 2 May 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 28 (8) , 2457-2464
Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study
Summary Determination of different forms of 25-OHD (total, free and bioavailable) in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values T), DBP, albumin, PTH and bone formation (PINP,OC) and resorption (NTx,CTx) markers. Free(25-OHDF) and bioavailable (25-OHDB) serum 25-OHD levels were estimated by DBP and albumin determinations and also directly by ELISA (25-OHDF-2). We analysed threshold PTH values for the different forms of 25-OHD and the correlations and differences according to 25-OHDT levels T (15.4 ± 1.4 vs. 18.3 ± 2.7, p < 0.05) and 25OHDB values (1.7 ± 0.2 vs. 2.2 ± 0.09, p < 0.05). The different forms of 25OHD were significantly intercorrelated, with marginal correlations between PTH and 25-OHDT (r = −0.136, p = 0.082). Conclusions Determination of different forms of 25-OHD in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values <15 ng/ml would be more appropriate for defining this deficiency.
- 1 November 2015
- Published by Elsevier in Revista Clínica Española
- Vol. 215 (8) , 476-478
El FRAX® español se ajusta más en la predicción de las fracturas femorales que en el resto de fracturas osteoporóticas. Resultados preliminares del estudio FRODOS
- 1 November 2015
- Published by Elsevier in Revista Clínica Española
- Vol. 215 (8) , 476-478
El FRAX® español se ajusta más en la predicción de las fracturas femorales que en el resto de fracturas osteoporóticas. Resultados preliminares del estudio FRODOS
- 6 March 2014
- Published by Springer Nature in Osteoporosis International
- Vol. 25 (5) , 1455-1464
Prevalence of vertebral fractures and minor vertebral deformities evaluated by DXA-assisted vertebral fracture assessment (VFA) in a population-based study of postmenopausal women: the FRODOS study
Population-based studies performed with vertebral fracture assessment (VFA) morphometric technology are lacking in postmenopausal osteoporosis. In this study, we show a lower than expected prevalence of vertebral fractures, a high prevalence of minor vertebral deformities, and a clear association with clinical and densitometric parameters indicating the usefulness of this approach. Adequate epidemiological data on the prevalence of vertebral fractures (VF) is essential in studies of postmenopausal osteoporosis. Routine DXA-assisted VFA may be useful to determine the presence of VF. However, population-based studies performed with this technology are lacking. We aimed to assess the prevalence of VF and minor deformities in 2,968 postmenopausal women aged 59–70 years from a population-based cohort. VFA and bone mineral density (BMD) measurements were conducted, and McCloskey criteria (vertebral heights under 3 SD from reference values) confirmed with the Genant method were used to define VF. Additionally, minor vertebral deformities (vertebral heights between −2 and −2.99 SD) were evaluated. The prevalence of VF was 4.3 %, and 17 % of the participants had minor vertebral deformities. Low BMD was frequently observed in women with VF, with 48 %, and 42 % of participants showing osteoporosis and osteopenia. Minor vertebral deformities were observed in nearly 40 % of women with VF. Multivariate logistic regression analysis showed that age, history of previous fracture, osteoporotic BMD, receiving anti-osteoporotic treatment, and current use of glucocorticoids were significantly associated with VF. Although the VFA approach showed a lower than expected prevalence of VF in our cohort, its association with clinical and densitometric parameters may be useful to identify women at risk for developing fragility fractures and may therefore justify its use in longitudinal studies. The high prevalence of minor vertebral deformities detected in patients with VF indicates the need to evaluate this type of deformity as a risk factor for further skeletal fractures.
- 6 March 2014
- Published by Springer Nature in Osteoporosis International
- Vol. 25 (5) , 1455-1464
Prevalence of vertebral fractures and minor vertebral deformities evaluated by DXA-assisted vertebral fracture assessment (VFA) in a population-based study of postmenopausal women: the FRODOS study
Population-based studies performed with vertebral fracture assessment (VFA) morphometric technology are lacking in postmenopausal osteoporosis. In this study, we show a lower than expected prevalence of vertebral fractures, a high prevalence of minor vertebral deformities, and a clear association with clinical and densitometric parameters indicating the usefulness of this approach. Adequate epidemiological data on the prevalence of vertebral fractures (VF) is essential in studies of postmenopausal osteoporosis. Routine DXA-assisted VFA may be useful to determine the presence of VF. However, population-based studies performed with this technology are lacking. We aimed to assess the prevalence of VF and minor deformities in 2,968 postmenopausal women aged 59–70 years from a population-based cohort. VFA and bone mineral density (BMD) measurements were conducted, and McCloskey criteria (vertebral heights under 3 SD from reference values) confirmed with the Genant method were used to define VF. Additionally, minor vertebral deformities (vertebral heights between −2 and −2.99 SD) were evaluated. The prevalence of VF was 4.3 %, and 17 % of the participants had minor vertebral deformities. Low BMD was frequently observed in women with VF, with 48 %, and 42 % of participants showing osteoporosis and osteopenia. Minor vertebral deformities were observed in nearly 40 % of women with VF. Multivariate logistic regression analysis showed that age, history of previous fracture, osteoporotic BMD, receiving anti-osteoporotic treatment, and current use of glucocorticoids were significantly associated with VF. Although the VFA approach showed a lower than expected prevalence of VF in our cohort, its association with clinical and densitometric parameters may be useful to identify women at risk for developing fragility fractures and may therefore justify its use in longitudinal studies. The high prevalence of minor vertebral deformities detected in patients with VF indicates the need to evaluate this type of deformity as a risk factor for further skeletal fractures.
- Open Access
- 1 March 2014
- Published by SciELO Espana/Repisalud in Revista de Osteoporosis y Metabolismo Mineral
- Vol. 6 (1) , 14-19
Riesgo de fractura en la cohorte FRODOS: estudio comparativo de la aplicación del modelo FRAX® español, francés, inglés y sueco
Fundamento y objetivos: Los estudios sobre validación del FRAX® en España muestran una infravaloración del riesgo de fracturas osteoporóticas principales (FOP) y predicciones más ajustadas para las fracturas femorales (FF). Se ha sugerido que este algoritmo podría mejorarse con datos más concretos de la epidemiología de las fracturas en España. Los objetivos de este trabajo fueron describir el riesgo basal de fracturas según el modelo español FRAX® en las participantes de la cohorte FRODOS y comparar estos datos con la aplicación de otros modelos europeos FRAX® en la misma cohorte. Métodos: Estudio observacional en una cohorte poblacional de 2.968 mujeres postmenopáusicas (59-70 años); se utilizó la versión online desktop de FRAX® para múltiples entradas de datos para calcular los riesgos de FOP y FF a 10 años aplicando los modelos español, francés, inglés y sueco en la misma cohorte. Resultados: El riesgo más bajo correspondió al modelo español: FF: 1,22% (36 fracturas esperadas) y FOP: 5,28% (n=197), mientras que el riesgo más alto fue el del modelo sueco: FF: 3,15% y FOP 13,51% (n=401). Los modelos de Francia y el Reino Unido presentaron valores intermedios. Conclusión: En una cohorte española de 2.968 mujeres postmenopáusicas el riesgo porcentual de fracturas esperadas a 10 años se incrementa con un gradiente de latitud sur-norte al aplicar diferentes modelos FRAX® europeos. Los resultados de incidencia de fracturas en la cohorte FRODOS previsto para los próximos años, confirmarán o no la utilidad del presente análisis.
- 1 March 2014
- Published by SciELO Espana/Repisalud in Revista de Osteoporosis y Metabolismo Mineral
- Vol. 6 (1) , 14-19
Open AccessRiesgo de fractura en la cohorte FRODOS: estudio comparativo de la aplicación del modelo FRAX® español, francés, inglés y sueco
Fundamento y objetivos: Los estudios sobre validación del FRAX® en España muestran una infravaloración del riesgo de fracturas osteoporóticas principales (FOP) y predicciones más ajustadas para las fracturas femorales (FF). Se ha sugerido que este algoritmo podría mejorarse con datos más concretos de la epidemiología de las fracturas en España. Los objetivos de este trabajo fueron describir el riesgo basal de fracturas según el modelo español FRAX® en las participantes de la cohorte FRODOS y comparar estos datos con la aplicación de otros modelos europeos FRAX® en la misma cohorte. Métodos: Estudio observacional en una cohorte poblacional de 2.968 mujeres postmenopáusicas (59-70 años); se utilizó la versión online desktop de FRAX® para múltiples entradas de datos para calcular los riesgos de FOP y FF a 10 años aplicando los modelos español, francés, inglés y sueco en la misma cohorte. Resultados: El riesgo más bajo correspondió al modelo español: FF: 1,22% (36 fracturas esperadas) y FOP: 5,28% (n=197), mientras que el riesgo más alto fue el del modelo sueco: FF: 3,15% y FOP 13,51% (n=401). Los modelos de Francia y el Reino Unido presentaron valores intermedios. Conclusión: En una cohorte española de 2.968 mujeres postmenopáusicas el riesgo porcentual de fracturas esperadas a 10 años se incrementa con un gradiente de latitud sur-norte al aplicar diferentes modelos FRAX® europeos. Los resultados de incidencia de fracturas en la cohorte FRODOS previsto para los próximos años, confirmarán o no la utilidad del presente análisis.
- 8 December 2012
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 31 (2) , 231-239
Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort)
This cross-sectional study evaluated the distribution of serum cross-linked C-telopeptides of collagen type I (βCTXs) in postmenopausal women, the characteristics of bone remodeling, and the factors influencing this bone marker, especially the use of anti-osteoporotic drugs. Women (n = 4,175) aged 59–70 years randomly selected from the community were invited to participate, measuring βCTXs and lumbar and femoral bone mineral density at recruitment. Risk factors for osteoporosis and the use of anti-osteoporotic treatment were collected with a structured questionnaire. We evaluated the percentage of women with increased (βCTXs >0.620 ng/mL) and decreased bone turnover (βCTXs βCTXs within the lower half of the reference range for healthy young premenopausal women). Two thousand nine hundred sixty-eight women (70 %) participated (2,405 non-treated and 563 treated). Increased and decreased bone turnover was observed in 16.4 and 1.8 %, respectively, of non-treated women with significant differences compared with treated women (9.7 and 14.2 %, respectively, p < 0.001); 28 % of non-treated osteoporotic individuals had increased bone turnover versus 14 % of osteopenic participants and 8.8 % of women with normal bone density (p < 0.001). Women receiving bisphosphonates presented the highest percentages of decreased bone turnover (27 %) and βCTXs (43 %) within the treatment target. Increased bone turnover is observed in 16.4 % of non-treated postmenopausal women and is more frequent in individuals with osteoporosis, whereas decreased bone turnover is unusual. Most participants taking bisphosphonates had values within the treatment target, but nearly one quarter had decreased bone turnover.
- 8 December 2012
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 31 (2) , 231-239
Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort)
This cross-sectional study evaluated the distribution of serum cross-linked C-telopeptides of collagen type I (βCTXs) in postmenopausal women, the characteristics of bone remodeling, and the factors influencing this bone marker, especially the use of anti-osteoporotic drugs. Women (n = 4,175) aged 59–70 years randomly selected from the community were invited to participate, measuring βCTXs and lumbar and femoral bone mineral density at recruitment. Risk factors for osteoporosis and the use of anti-osteoporotic treatment were collected with a structured questionnaire. We evaluated the percentage of women with increased (βCTXs >0.620 ng/mL) and decreased bone turnover (βCTXs βCTXs within the lower half of the reference range for healthy young premenopausal women). Two thousand nine hundred sixty-eight women (70 %) participated (2,405 non-treated and 563 treated). Increased and decreased bone turnover was observed in 16.4 and 1.8 %, respectively, of non-treated women with significant differences compared with treated women (9.7 and 14.2 %, respectively, p < 0.001); 28 % of non-treated osteoporotic individuals had increased bone turnover versus 14 % of osteopenic participants and 8.8 % of women with normal bone density (p < 0.001). Women receiving bisphosphonates presented the highest percentages of decreased bone turnover (27 %) and βCTXs (43 %) within the treatment target. Increased bone turnover is observed in 16.4 % of non-treated postmenopausal women and is more frequent in individuals with osteoporosis, whereas decreased bone turnover is unusual. Most participants taking bisphosphonates had values within the treatment target, but nearly one quarter had decreased bone turnover.